<DOC>
	<DOC>NCT01144975</DOC>
	<brief_summary>The study hypothesis is that XOMA 052 is likely to improve glycemic control in subjects with Type 2 Diabetes Mellitus. The purpose of this study is to determine whether XOMA 052 improves glycemic control in subjects on Metformin monotherapy whose diabetes is still not adequately controlled.</brief_summary>
	<brief_title>Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Diagnosed with T2D (disease duration &gt;= 6 months) HbA1c measurements &gt;= 7.0% and &lt;= 10.0% On a stable regimen of metformin monotherapy Age &gt;= 18 and &lt;= 75 Stable diet and exercise regimen BMI &lt;= 40 kg/m2 Significant signs and symptoms of uncontrolled hyperglycemia (i.e., polyuria, polydipsia, or polyphagia) Uncontrolled hypertension (systolic &gt; 170 mmHg and/or diastolic &gt; 110 mmHg) Known to be positive for Hep B surface antigen (HBsAg), Hep C virus (HCV), or HIV History of allergic or anaphylactic reactions to humanized or murine monoclonal antibodies Advanced stage heart failure (New York Heart Association [NYHA] class 3 or 4) Pulmonary disease requiring medication other than inhaled corticosteroid s History of tuberculosis or positive PPD test. Active leg, foot, or decubitus ulcer Any significant inflammatory, rheumatologic, or systemic autoimmune disease History or any symptoms of a demyelinating disease History of severe nonproliferative or proliferative retinopathy Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Mellitus</keyword>
</DOC>